CGTX Cognition Therapeutics Inc. Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
Cognition Therapeutics (CGTX) specializes in identifying treatments for neuronal degradation, outsourcing drug development and primary testing to third-party contractors. Strict control over the movement of biomaterials ensures the accuracy of the research. The current EV/EBITDA ratio stands at 0.00. The price action for the company shown on this chart reflects the impact of a strategy to expand its network of partner laboratories to accelerate the verification of new drugs.
Analytical breakdowns for Cognition Therapeutics
- current price and projected stock value:
- market capitalization data:
- book value of equity indicators:
- company total debt and liquidity indicators:
Total Debt to Capital Cognition Therapeutics|CGTX - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity cogrx.com|CGTX - Company Cumulative Debt|Debt to Book Capitalization Ratio Cognition Therapeutics|CGTX - Company Long-Term Indebtedness|Company Current Liabilities Cognition Therapeutics|Quick Liquidity Indicator cogrx.com
- financial results and valuation multiples details:
CGTX - Profit After Payment of Taxes|Projected Future Earnings Cognition Therapeutics|CGTX - Company Value to Net Income|Forward P/E Multiple Cognition Therapeutics Inc.|CGTX - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cognition Therapeutics Inc.|CGTX - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Cognition Therapeutics|CGTX - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months cogrx.com|CGTX - Earnings per share trend in current year|Earnings growth forecast for next year Cognition Therapeutics
- sales volume and revenue indicators:
Initial company analysis:CGTX (Cognition Therapeutics, Inc.)
Investors utilize this screening to determine an issuer's financial stability under high leverage. The metric compares the total enterprise value, including net debt, with operating profit before depreciation and amortization to reveal the actual value of assets. For Cognition Therapeutics (CGTX), which invests in the development of Alzheimer's disease treatments, this calculation is critical due to the capital intensity of R&D. Analyzing the EV/EBITDA multiple for a capital-intensive enterprise allows for the timely identification of undervaluation or default risk.
Competitor analysis for Cognition Therapeutics
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Biogen Inc BIIB|EV/EBITDA Multiple neurocrine.com NBIX|RGC - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Axsome|ACAD: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation XENE|VKTX (Viking Therapeutics Corp) - EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation SUPN (Supernus)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Catalyst Pharma (CPRX)|DNLI (Denali Therapeutics Inc) - Business Value to Operating Income Before Depreciation|Harmony Pharma - Enterprise Value to EBITDA Ratio|BHVN: Enterprise Value to Operating Income Before Depreciation|Amylyx Pharmaceuticals - EV/EBITDA Multiple|Company Value to EBITDA trevitherapeutics.com|PRAX: EV/EBITDA Multiple|Company Value to Operating Income Before Depreciation Ratio AVXL (Anavex Life Sciences Corp.)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CeriBell, Inc.|Company Value to EBITDA Prothena Biosciences PRTA|Enterprise Value to EBITDA Ratio ALEC (Alector Therapeutics)|Total Company Value to Operating Income Before Depreciation Ratio Annexon, Inc.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Omeros Corporation OMER|NGNE - Enterprise Value to EBITDA Ratio|ACIU - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio VYGR|NMRA: EV/EBITDA Multiple|Scilex Holding Company - Business Value to Operating Income Before Depreciation|TVGN (Tevogen Bio Holdings, Inc.) - EV/EBITDA Multiple|EV/EBITDA Multiple Alpha Cognition|EV/EBITDA Multiple IKT|SAVA (Cassava) - Business Value to Operating Income Before Depreciation|Assertio Holdings, Inc. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation COYA|VistaGen Therapeutics, Inc. - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Ovid Therapeutics OVID|ABOS: EV/EBITDA Multiple|CervoMed Corporation (CRVO) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alterity Therapeutics Limited|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CLNN|EV/EBITDA Multiple PEPG|JUNS (Jupiter Neurosciences) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Relmada Corp RLMD|EV/EBITDA Multiple Annovis Bio Corporation ANVS|gracetx.com - EV/EBITDA Multiple|Firefly Neuroscience, Inc (AIFF) - Enterprise Value to EBITDA Ratio|Klotho Neurosciences (KLTO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|NeuroSense Therapeutics, Ltd. - Business Value to Operating Income Before Depreciation|RVPH (Reviva Pharmaceuticals Holdings) - EV/EBITDA Multiple|MetaVia Inc (MTVA) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple NRXS|Total Company Value to Operating Income Before Depreciation Ratio Helius Medical Technologies Inc.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization passagebio.com PASG|NEUP: Enterprise Value to Operating Income Before Depreciation|NERV - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Athira - Enterprise Value to Operating Income Before Depreciation Ratio|ADXN: EV/EBITDA Multiple|ALZN (Alzamend Neuro, Inc.) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cyclerion Therapeutics Inc.|PTIX: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple KTTA|Enterprise Value to Operating Income Before Depreciation Ratio CRGT|Avenue Therapeutics Inc - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation BCLI|CARA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation CHRO (Chromocell Therapeutics Corp)|ELYM: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation ITCI|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Longboard Pharmaceuticals Inc|marinuspharma.com (MRNS) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio NKGN (NKGen Biotech, Inc.)|NRBO - Company Value to EBITDA|EV/EBITDA Multiple SAGE (Sage Therapeutics, Inc)|SNPX: Enterprise Value to Operating Income Before Depreciation|Trevena Inc. - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio vigilneuro.com VIGL|WENA: EV/EBITDA Multiple|Company Value to EBITDA Cerevel Therapeutics Inc (CERE)
